JP2022511776A5 - - Google Patents

Info

Publication number
JP2022511776A5
JP2022511776A5 JP2021530078A JP2021530078A JP2022511776A5 JP 2022511776 A5 JP2022511776 A5 JP 2022511776A5 JP 2021530078 A JP2021530078 A JP 2021530078A JP 2021530078 A JP2021530078 A JP 2021530078A JP 2022511776 A5 JP2022511776 A5 JP 2022511776A5
Authority
JP
Japan
Prior art keywords
approximately
administration
less
composition according
months
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021530078A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022511776A (ja
JP7677887B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/063649 external-priority patent/WO2020113034A1/en
Publication of JP2022511776A publication Critical patent/JP2022511776A/ja
Publication of JP2022511776A5 publication Critical patent/JP2022511776A5/ja
Priority to JP2024213225A priority Critical patent/JP7808674B2/ja
Application granted granted Critical
Publication of JP7677887B2 publication Critical patent/JP7677887B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021530078A 2018-11-30 2019-11-27 Aavウイルスベクター及びその使用 Active JP7677887B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024213225A JP7808674B2 (ja) 2018-11-30 2024-12-06 Aavウイルスベクター及びその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862773894P 2018-11-30 2018-11-30
US62/773,894 2018-11-30
US201962835242P 2019-04-17 2019-04-17
US62/835,242 2019-04-17
PCT/US2019/063649 WO2020113034A1 (en) 2018-11-30 2019-11-27 Aav viral vectors and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024213225A Division JP7808674B2 (ja) 2018-11-30 2024-12-06 Aavウイルスベクター及びその使用

Publications (3)

Publication Number Publication Date
JP2022511776A JP2022511776A (ja) 2022-02-01
JP2022511776A5 true JP2022511776A5 (enExample) 2022-12-01
JP7677887B2 JP7677887B2 (ja) 2025-05-15

Family

ID=69167903

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021530078A Active JP7677887B2 (ja) 2018-11-30 2019-11-27 Aavウイルスベクター及びその使用
JP2024213225A Active JP7808674B2 (ja) 2018-11-30 2024-12-06 Aavウイルスベクター及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024213225A Active JP7808674B2 (ja) 2018-11-30 2024-12-06 Aavウイルスベクター及びその使用

Country Status (12)

Country Link
US (1) US20220001028A1 (enExample)
EP (1) EP3886919A1 (enExample)
JP (2) JP7677887B2 (enExample)
KR (1) KR20210099025A (enExample)
CN (2) CN120860258A (enExample)
AU (1) AU2019389047A1 (enExample)
BR (1) BR112021009739A2 (enExample)
CA (1) CA3116630A1 (enExample)
IL (1) IL282885A (enExample)
MX (1) MX2021006359A (enExample)
TW (2) TWI844587B (enExample)
WO (1) WO2020113034A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210308281A1 (en) * 2018-08-15 2021-10-07 Biogen Ma Inc. Combination therapy for spinal muscular atrophy
TW202140791A (zh) * 2020-01-13 2021-11-01 美商霍蒙拉奇醫藥公司 治療苯酮尿症之方法
CN112121179A (zh) * 2020-09-15 2020-12-25 山东兴瑞生物科技有限公司 一种组合物及其在治疗脊髓性肌萎缩症中的应用
WO2022155364A1 (en) * 2021-01-13 2022-07-21 Dignity Health Modulation of chitinase protein expression
CA3227103A1 (en) 2021-07-30 2023-02-02 Matthew P. GEMBERLING Compositions and methods for modulating expression of frataxin (fxn)
US20240252684A1 (en) 2021-07-30 2024-08-01 Tune Therapeutics, Inc. Compositions and methods for modulating expression of methyl-cpg binding protein 2 (mecp2)
EP4380602A4 (en) * 2021-08-03 2025-06-11 The Regents Of The University Of California ADENO-ASSOCIATED VIRAL (AAV)-MEDIATED EXPRESSION OF SPHINGOSINE 1-PHOSPHATE LYASE (SPL) FOR THE TREATMENT OF PULMONARY FIBROSIS
CN114276419B (zh) * 2021-12-30 2023-11-17 上海勉亦生物科技有限公司 肌肉高亲和性的新型腺相关病毒衣壳蛋白及其应用
KR20230152503A (ko) * 2022-04-27 2023-11-03 주식회사 헬릭스미스 척수강 내 투여에 최적화 된 간세포 성장인자 유전자가 도입된 aav 벡터
WO2023219394A1 (ko) * 2022-05-10 2023-11-16 서울대학교산학협력단 인간 smn1 단백질 변이체 및 이의 용도
US20250369012A1 (en) 2022-06-21 2025-12-04 Skyline Therapeutics Limited Recombinant aav for the gene therapy of sma disease
CA3261865A1 (en) 2022-07-12 2024-01-18 Tune Therapeutics, Inc. TARGETED TRANSCRIPTIONAL ACTIVATION COMPOSITIONS, SYSTEMS AND METHODS
WO2024163678A2 (en) 2023-02-01 2024-08-08 Tune Therapeutics, Inc. Fusion proteins and systems for targeted activation of frataxin (fxn) and related methods
WO2024163683A2 (en) 2023-02-01 2024-08-08 Tune Therapeutics, Inc. Systems, compositions, and methods for modulating expression of methyl-cpg binding protein 2 (mecp2) and x-inactive specific transcript (xist)
EP4713028A1 (en) * 2023-05-18 2026-03-25 Ultragenyx Pharmaceutical Inc. Formulations comprising recombinant aav and methods of administering the same
WO2026028089A1 (en) 2024-07-29 2026-02-05 Novartis Ag Compositions and methods for the treatment of lysosomal acid lipase deficiency (lal-d)

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
PT728214E (pt) 1993-11-09 2004-11-30 Ohio Med College Linhas celulares estaveis capazes de expressar o gene de replicacao do virus adeno-associado
WO1995013365A1 (en) 1993-11-09 1995-05-18 Targeted Genetics Corporation Generation of high titers of recombinant aav vectors
US5658785A (en) 1994-06-06 1997-08-19 Children's Hospital, Inc. Adeno-associated virus materials and methods
US5856152A (en) 1994-10-28 1999-01-05 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV vector and methods of use therefor
CA2207927A1 (en) 1994-12-06 1996-06-13 Targeted Genetics Corporation Packaging cell lines for generation of high titers of recombinant aav vectors
FR2737730B1 (fr) 1995-08-10 1997-09-05 Pasteur Merieux Serums Vacc Procede de purification de virus par chromatographie
WO1997008298A1 (en) 1995-08-30 1997-03-06 Genzyme Corporation Chromatographic purification of adenovirus and aav
US6632670B1 (en) 1995-09-08 2003-10-14 Genzyme Corporation AAV vectors for gene therapy
US5910434A (en) 1995-12-15 1999-06-08 Systemix, Inc. Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant
DK1009808T3 (da) 1997-09-05 2013-01-21 Genzyme Corp Fremgangsmåder til generering af hjælper-frie præparater af rekombinante aav-vektorer med høj titer
US6258595B1 (en) 1999-03-18 2001-07-10 The Trustees Of The University Of Pennsylvania Compositions and methods for helper-free production of recombinant adeno-associated viruses
US7056502B2 (en) 2000-04-28 2006-06-06 The Trustees Of The University Of Pennsylvania Recombinant aav vectors with AAV5 capsids and AAV5 vectors pseudotyped in heterologous capsids
DK2573170T3 (en) 2001-12-17 2018-04-09 Univ Pennsylvania Sequences of adeno-associated virus (AAV) serotype 9, vectors containing them, and their use
US9233131B2 (en) 2003-06-30 2016-01-12 The Regents Of The University Of California Mutant adeno-associated virus virions and methods of use thereof
US9441244B2 (en) 2003-06-30 2016-09-13 The Regents Of The University Of California Mutant adeno-associated virus virions and methods of use thereof
EP2345731B1 (en) * 2003-09-30 2015-10-21 The Trustees of the University of Pennsylvania Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses thereof
EP3470072A1 (en) 2005-06-23 2019-04-17 Biogen MA Inc. Compositions and methods for modulation of smn2 splicing
ES2699827T3 (es) 2009-06-17 2019-02-13 Biogen Ma Inc Composiciones y métodos para la modulación de corte y empalme de SMN2 en un sujeto
WO2011094198A1 (en) * 2010-01-28 2011-08-04 The Children's Hospital Of Philadelphia Research Institute, Abramson Research Center A scalable manufacturing platform for viral vector purification and viral vectors so purified for use in gene therapy
DE102012007232B4 (de) 2012-04-07 2014-03-13 Susanne Weller Verfahren zur Herstellung von rotierenden elektrischen Maschinen
AU2013296425B2 (en) * 2012-08-01 2018-06-07 Nationwide Children's Hospital Intrathecal delivery of recombinant adeno-associated virus 9
MX380973B (es) * 2013-05-01 2025-03-12 Genzyme Corp Composiciones y metodos para tratar la atrofia muscular espinal.
CN115120746A (zh) * 2013-05-15 2022-09-30 明尼苏达大学董事会 腺相关病毒介导的基因向中枢神经系统转移
JP2015092462A (ja) 2013-09-30 2015-05-14 Tdk株式会社 正極及びそれを用いたリチウムイオン二次電池
AU2014340149B2 (en) * 2013-10-22 2020-12-24 Shire Human Genetic Therapies, Inc. CNS delivery of mRNA and uses thereof
CA2942515C (en) * 2014-03-18 2025-12-09 University Of Massachusetts Raav-based compositions and methods for treating amyotrophic lateral sclerosis
WO2015141521A1 (ja) 2014-03-21 2015-09-24 株式会社日立国際電気 基板処理装置、半導体装置の製造方法及び記録媒体
JP6197169B2 (ja) 2014-09-29 2017-09-20 東芝メモリ株式会社 半導体装置の製造方法
CA3068328A1 (en) * 2017-07-06 2019-01-10 The Trustees Of The University Of Pennsylvania Aav9-mediated gene therapy for treating mucopolysaccharidosis type i
WO2019094253A1 (en) * 2017-11-08 2019-05-16 Avexis Inc. Means and method for preparing viral vectors and uses of same

Similar Documents

Publication Publication Date Title
JP2022511776A5 (enExample)
JP2025060641A5 (enExample)
Ponikau et al. Intranasal antifungal treatment in 51 patients with chronic rhinosinusitis
TWI897418B (zh) Aav病毒載體及其用途
JP2024517143A5 (enExample)
US20210145929A1 (en) Aav compositions, methods of making and methods of use
WO2025038800A1 (en) Compositions and methods for the treatment of disorders related to frataxin deficiency
WO2023057404A1 (en) Novel combined administration
AU2003257675A1 (en) Biomolecule transfer method using virus envelope and composition and system therefor
EP4509606A1 (en) Nucleic acid construct for treating hereditary coagulation factor deficiency and use thereof
US9872895B2 (en) TLR5 ligands, therapeutic methods, and compositions related thereto
JP2008516994A (ja) 成長ホルモン分泌促進因子およびその使用
CN121152634A (zh) 用于治疗恶心和呕吐的方法和用途
RU2021118669A (ru) Вирусные векторы на основе aav и пути их применения
Sanchez et al. Transduction of PACAP38 protects primary cortical neurons from neurotoxic injury
JP2022518354A5 (enExample)
CN117616121A (zh) 寡核苷酸用于具有肾脏损伤的个体的用途
US12544392B2 (en) Treatment of adenovirus infection or disease associated with adenovirus infection
JP3034032B2 (ja) 腸疾患用薬剤
RU2796274C2 (ru) Вирусные векторы на основе aav и пути их применения
Lester et al. Adverse reactions to cromolyn sodium: patient report and review of the literature
JP2023526311A5 (enExample)
AU2023348282A1 (en) Glucagon-like-peptide-2 (glp-2) analogues and their medical uses for the treatment of short bowel syndrome (sbs)
WO2022068847A1 (zh) 一种治疗或预防新型冠状病毒SARS-CoV-2引起的疾病的方法
TW202606762A (zh) 治療t細胞淋巴瘤之組合物及方法